Breaking news

CIFA: A Year Of Strategic Growth And Opportunity For Investment Funds In 2025

by THEFUTURE.TEAM

January 9, 2025

The Cyprus Investment Funds Association (CIFA) is stepping into 2025 with renewed confidence, building on the significant achievements of the past years. Despite the global uncertainties that continue to unfold, Cyprus’ Investment Funds sector has firmly established itself as a vital contributor to the nation’s economic and social prosperity.

In 2024, Cyprus reached a major milestone, surpassing €9.3 billion in assets under management. This remarkable achievement highlights the sector’s impressive growth and resilience. The year also marked an expansion of Cyprus’ global presence, attracting new fund managers and investment opportunities, further cementing its status as a leading European hub for Investment Funds. This success was driven by strategic collaborations and the dedicated efforts of professionals within the sector, fostering the creation of specialized job roles and reinforcing Cyprus’ position as a robust financial centre.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Looking ahead to 2025, CIFA remains fully committed to promoting Cyprus as the premier destination for global investment funds. By working alongside key stakeholders, including the Ministry of Finance, the Cyprus Securities and Exchange Commission, and Invest Cyprus, CIFA aims to enhance the regulatory framework and drive innovative solutions for the industry. The timely approval of pending legislation that modernizes regulatory processes and introduces new investment structures is crucial for unlocking the full potential of the sector. These updates will provide the industry with the necessary tools to stay competitive and aligned with international best practices. CIFA urges all stakeholders to prioritize this agenda to ensure Cyprus continues to attract high-quality investments and talent.

In addition, CIFA recognises the importance of equipping individuals and businesses with essential financial knowledge. In 2025, the association plans to roll out initiatives designed to boost financial literacy across Cyprus. These will include workshops, partnerships, and digital campaigns aimed at enhancing understanding of investment funds and financial planning. By empowering citizens and professionals with the knowledge to make informed financial decisions, CIFA is contributing to the long-term economic resilience of Cyprus.

Maria Panayiotou, President of CIFA, shares her outlook for the year: “The success of the Investment Funds sector is a reflection of our adaptability, innovation, and ability to thrive in a competitive global market. In 2025, our focus will be on sustainability, technology-driven solutions, and strengthening our partnerships across markets. Our goal is to drive economic growth while delivering lasting value for society. With the combined expertise and dedication of our sector, I am confident that we will continue to play a transformative role in Cyprus’ economy, fostering resilience and creating opportunities for all.”

As Cyprus embarks on a year of revitalisation and resilience, CIFA remains steadfast in advocating for the interests of its members, elevating Cyprus on the international stage, and supporting initiatives that promote sustainable development within the financial sector. The association calls on all stakeholders to collaborate in advancing the innovation, sustainability, and resilience that will define Cyprus’ financial future.

The Future Forbes Realty Global Properties

MammoCheck Secures A €500,000 SEED Grant From The RIF To Advance Toward FDA 510(k) Clearance And EU MDR CE Marking

by News Editor

August 4, 2026

The project is co-funded by the European Union and the Republic of Cyprus under the Cohesion Policy Programme THALIA 2021–2027. Frederick Research Center is participating as a partner organisation, continuing the company’s roots as a spin-out of Frederick University.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

NICOSIA, CYPRUS, July 31, 2026. MammoCheck Ltd, a Cyprus-based medical technology company founded as a spin-out of Frederick University, has secured a €500,000 grant under the Research and Innovation Foundation’s (RIF) SEED programme.

The competitive grant will support the continued development of the company’s adjunctive, research-validated software platform, which combines thermal imaging with artificial intelligence to support breast cancer screening. More specifically, the funding will support the clinical, quality management and regulatory work required as the company advances toward FDA 510(k) clearance in the United States and CE marking under the EU Medical Device Regulation (MDR 2017/745).

The RIF’s SEED programme supports innovative Cypriot start-ups developing internationally competitive products and services. It is co-funded by the European Union through the European Regional Development Fund and the Republic of Cyprus under the Cohesion Policy Programme THALIA 2021–2027.

For MammoCheck, the funding will support completion of its clinical programme, further development of its quality management system in line with ISO 13485, and preparation of the technical documentation and submissions required for the FDA and EU MDR regulatory pathways.

About MammoCheck

MammoCheck is developing a Software as a Medical Device (SaMD) platform that combines a smartphone application, thermal imaging and a proprietary artificial intelligence algorithm to support breast cancer screening.

Founded in 2024 as a spin-out of Frederick University, the company aims to address unequal access to screening. Mammography coverage remains highly uneven worldwide and has been reported as low as 1.7% in some countries, including among many women under the age of 45 who fall outside most national screening programmes.

The platform is being developed for use in primary care and gynaecology settings, as well as for guided home use, with every result reviewed by a clinician. It is intended to complement, rather than replace, established imaging modalities such as mammography and ultrasound.

MammoCheck is currently conducting a clinical study across hospital sites in Cyprus, approved by the Cyprus National Bioethics Committee.

The Role Of Frederick University

Frederick University continues to support the initiative as the institution from which MammoCheck originated. The collaboration also continues through the participation of the Frederick Research Center as a partner organisation in the funded project.

The centre contributes specialised expertise and infrastructure through its Nursing Department and the Mobile Devices Laboratory, focusing on artificial intelligence, smart systems and scientific dissemination. The collaboration strengthens the connection between Cypriot academic research and internationally oriented innovation.

The Frederick team supporting the project includes Dr. Andreas Constantinides, Associate Professor and Director of the Mobile Devices Laboratory, Dr. Evanthia Asimakopoulou, Assistant Professor in the Nursing Department, and Dr. Elena Papoui, Visiting Lecturer in the Nursing Department.

What The Grant Means

The award adds to a period of continued momentum for the company. Alongside its clinical and regulatory progress, MammoCheck is conducting a private investment round to accelerate commercial deployment as it advances toward key regulatory milestones.

The company also holds a Certificate of Innovative Enterprise from the Cyprus Deputy Ministry of Research, Innovation and Digital Policy, allowing eligible investors participating in the funding round to benefit from tax incentives under Cyprus’ innovation investment legislation.

Statements

“Securing €500,000 in competitive, non-dilutive funding is a strong vote of confidence in our vision, our team and our mission. It allows us to focus on what truly matters right now, turning that vision into reality, step by step, as we move steadily toward FDA 510(k) clearance and CE marking under the EU MDR,” said Alexandra Dimitriadou, Co-Founder and CEO of MammoCheck.

Athina Grigoriou, Co-Founder and CRO, added: “Our clinical programme is at the heart of this project. This support strengthens the study we are conducting across hospital sites in Cyprus and the evidence base behind every step of our regulatory pathway.”

Marios Pafitis, Co-Founder and CTO, said: “Working alongside the Frederick Research Center brings academic rigour to our engineering. This grant helps us take the technology from promising research toward a rigorously engineered and clinically validated product.”

The MammoCheck co-founding team, Alexandra Dimitriadou, Marios Pafitis and Athina Grigoriou, was named to the Forbes 30 Under 30 Greece list in 2026.

The MAMMOCHECK project (SEED/0525(B)/0102) is implemented under the Cohesion Policy Programme THALIA 2021–2027 and is co-funded by the European Union through the European Regional Development Fund and the Republic of Cyprus via the Research and Innovation Foundation.